KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $2.4 million.

  • Neogenomics' Change in Receivables fell 5115.51% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 9423.6%. This contributed to the annual value of $19.3 million for FY2024, which is 6770.58% up from last year.
  • Per Neogenomics' latest filing, its Change in Receivables stood at $2.4 million for Q3 2025, which was down 5115.51% from -$1.1 million recorded in Q2 2025.
  • Neogenomics' 5-year Change in Receivables high stood at $9.1 million for Q1 2024, and its period low was -$3.9 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Receivables was $718000.0 (2022), whereas its average is $2.4 million.
  • Per our database at Business Quant, Neogenomics' Change in Receivables crashed by 16852.5% in 2021 and then surged by 127145.83% in 2023.
  • Quarter analysis of 5 years shows Neogenomics' Change in Receivables stood at $7.2 million in 2021, then rose by 7.69% to $7.7 million in 2022, then plummeted by 118.3% to -$1.4 million in 2023, then skyrocketed by 37.11% to -$888000.0 in 2024, then soared by 366.67% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, -$1.1 million for Q2 2025, and $668000.0 during Q1 2025.